Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Fluoxetine prevents dystrophic changes in a zebrafish model of Duchenne muscular dystrophy.

Human molecular genetics - 1 Sept 2014

Waugh Trent A, Horstick Eric, Hur Junguk, Jackson Samuel W, Davidson Ann E, Li Xingli, Dowling James J

Abstract excerpt

Duchenne muscular dystrophy (DMD) is a common and relentlessly progressive muscle disease. Some interventions have been identified that modestly slow progression and prolong survival, but more meaningful therapies are lacking. The goal of this study is to identify new therapeutic pathways for DMD using a zebrafish model of the disease. To accomplish this, we performed a non-biased drug screen in sapje, a...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Drug Evaluation, Preclinical
Share to Dystrophin

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Fluoxetine

Share to Morpholinos

Share to Muscular Dystrophy, Animal

Share to Muscular Dystrophy, Duchenne

Share to Serotonin Plasma Membrane Transport Proteins

Share to Stress, Mechanical

Source

Open in PubMed Open full text

Identifiers

PMID: 24760771
DOI: 10.1093/hmg/ddu185
PMCID: PMC4119416

Genes

DMD

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Fluoxetine prevents dystrophic changes in a zebrafish model of Duchenne muscular dystrophy.PMID 24760771Read ↗

Drug screening in a zebrafish model of Duchenne muscular dystrophy.Semantic proximity Read ↗

Epigenetic small molecule screening identifies a new HDACi compound for ameliorating Duchenne muscular dystrophySemantic proximity Read ↗

Dystrophic muscle improvement in zebrafish via increased heme oxygenase signalingSemantic proximity Read ↗

Recent advances using zebrafish animal models for muscle disease drug discoverySemantic proximity Read ↗

Muscular dystrophy modeling in zebrafish.Semantic proximity Read ↗

Standardization of zebrafish drug testing parameters for muscle diseasesSemantic proximity Read ↗

A novel chemical-combination screen in zebrafish identifies epigenetic small molecule candidates for the treatment of Duchenne muscular dystrophySemantic proximity Read ↗

Duchenne muscular dystrophy animal models for high-throughput drug discovery and precision medicine.Semantic proximity Read ↗

Flight for fish in drug discovery: a review of zebrafish-based screening of molecules.Semantic proximity Read ↗

A novel drug-combination screen in zebrafish identifies epigenetic small molecule candidates for Duchenne muscular dystrophySemantic proximity Read ↗

[Therapeutic drug screening with zebrafish models].Semantic proximity Read ↗

Characterization of a C9orf72 Knockout Danio rerio model for ALS and cross-species validation of potential therapeutics screened in Caenorhabditis elegans.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.